Relevant bibliographies by topics / Polymorphous low-grade adenocarcinoma

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters

Academic literature on the topic 'Polymorphous low-grade adenocarcinoma'

Author: Grafiati
Published: 4 June 2021
Last updated: 19 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Polymorphous low-grade adenocarcinoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Polymorphous low-grade adenocarcinoma"

1

Bernido, Joy B., and Jose M. Carnate. "Polymorphous Low-Grade Adenocarcinoma." Philippine Journal of Otolaryngology-Head and Neck Surgery 29, no. 2 (2014): 39–40. http://dx.doi.org/10.32412/pjohns.v29i2.433.

Full text
Abstract:
A 60-year-old woman with a 3-year history of a gingivoalveopalatal mass underwent an incision biopsy.
 Microscopically, the lesion centered in the stroma is infiltrative (Fig. 1) and architecturally diverse, having cystic (Fig. 2), linear or “Indian file” (Fig. 3), solid, and tubular (Fig. 4) patterns. The cells are uniform in size, round to oval, and have bland cytologic features, with vesicular nuclei and inconspicuous nucleoli (Figure 4). The clinical data and histomorphologic features characterized by architectural diversity yet cytologic blandness lead us to the diagnosis of polymorphous low-grade adenocarcinoma. 
 Polymorphous low-grade adenocarcinoma (PLGA) is a malignant epithelial tumor characterized by cytologic uniformity, morphologic diversity, an infiltrative growth pattern, and low metastatic potential.1 It is the second most common intraoral malignant salivary gland tumor 1 following mucoepidermoid carcinoma. The tumor is found almost exclusively in minor salivary glands and is rare in extraoral locations, including major salivary glands.2 The tumor affects a wide age range (16 – 95 years; mean 60 years), with only 2 pediatric cases reported,1 and has a female predilection.3,4 It usually presents as a painless mass located within the oral cavity,3 60% of which are located in the palate.1 They are characteristically unencapsulated, although well-circumscribed.3 
 
 This entity is architecturally diverse (“polymorphous”) even within a single tumor, with solid, tubular, trabecular, cribriform, papillary and linear patterns being described. Perineural invasion is common although it was not seen in this case. The tumor cells are small to medium sized, and uniformly round to polygonal. The nuclei are bland and vesicular, with occasional small inconspicuous nucleoli. Mitotic figures can be found occasionally but are never numerous.3, 8
 
 The morphologic heterogeneity in small biopsies and frozen section samples can be confused with pleomorphic adenoma and adenoid cystic carcinoma.6,7 Glial fibrillary acid protein may help as PLGA is typically non-reactive in contrast to pleomorphic adenoma.2 De Araujo and others site that uniformly positive vimentin, CK7, and S100 staining favors PLGA over adenoid cystic carcinoma.6 Tumor cytology and histology are quite characteristic - recognizing the constant cytological appearance despite the diversity of architectural tumor patterns should aid one in diagnosing PLGA.
 PLGA, despite its infiltrative growth pattern and propensity for perineural invasion, usually runs an indolent course. Nodal metastasis and distant spread are rare, occurring in less than 1% of cases.4 Seethala and others report that extrapalatal location is associated with a more aggressive clinical course.5 Complete surgical excision is the primary treatment with neck dissection reserved for nodal metastasis.1 One-third of patients may have a local recurrence and lifelong monitoring is suggested. Re-excision is amenable in these cases.5,6
APA, Harvard, Vancouver, ISO, and other styles
2

Mhaske, Shubhangi, Raju Ragavendra T, Sandeep S Gupta, Kavitha P Kamath, and Anil Ghom. "Polymorphous Low-Grade Adenocarcinoma." Journal of Indian Academy of Oral Medicine and Radiology 22 (September 15, 2010): S67—S68. http://dx.doi.org/10.5005/jp-journals-10011-1075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chatura, KR. "Polymorphous low grade adenocarcinoma." Journal of Oral and Maxillofacial Pathology 19, no. 1 (2015): 77. http://dx.doi.org/10.4103/0973-029x.157206.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Evans, Harry L., and Mario A. Luna. "Polymorphous Low-Grade Adenocarcinoma." American Journal of Surgical Pathology 24, no. 10 (2000): 1319–28. http://dx.doi.org/10.1097/00000478-200010000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fife, Tim, Brooks Smith, and Joshua Waltonen. "Polymorphous Low-Grade Adenocarcinoma." Otolaryngology–Head and Neck Surgery 145, no. 2_suppl (2011): P174—P175. http://dx.doi.org/10.1177/0194599811415823a133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gottlieb, Jonathan B., Michael Joachim, Yoav Leiser, Murad Abdelraziq, and Imad Abu El-Naaj. "Polymorphous Low-Grade Adenocarcinoma." Journal of Craniofacial Surgery 30, no. 4 (2019): 1228–30. http://dx.doi.org/10.1097/scs.0000000000005328.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Thompson, Lester D. R. "Polymorphous Low-Grade Adenocarcinoma." Pathology Case Reviews 9, no. 6 (2004): 259–63. http://dx.doi.org/10.1097/01.pcr.0000143777.29141.ea.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Akosa, A. B. "Polymorphous low-grade adenocarcinoma." Histopathology 20, no. 6 (2007): 549–50. http://dx.doi.org/10.1111/j.1365-2559.1992.tb01047.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Simpson, R. H. W., T. I. Clarke, P. T. L. Sarsfield, P. G. C. Gluckman, and A. V. Babajews. "Polymorphous low-grade adenocarcinoma." Histopathology 20, no. 6 (2007): 550–51. http://dx.doi.org/10.1111/j.1365-2559.1992.tb01048.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kelsch, Robert D., Tawfiqul Bhuiya, Alexander Fuchs, Pam Gentile, Michael A. Kahn, and John E. Fantasia. "Polymorphous low-grade adenocarcinoma." Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 84, no. 4 (1997): 391–99. http://dx.doi.org/10.1016/s1079-2104(97)90037-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Polymorphous low-grade adenocarcinoma"

1

Ferrazzo, Kivia Linhares. ""Expressão imunoistoquímica da proteína galectina-3 em carcinoma adenóide cístico e adenocarcinoma polimorfo de baixo grau de malignidade de glândulas salivares"." Universidade de São Paulo, 2006. http://www.teses.usp.br/teses/disponiveis/23/23141/tde-28082006-193724/.

Full text
Abstract:
O carcinoma adenóide cístico e o adenocarcinoma polimorfo de baixo grau de malignidade são neoplasias malignas das glândulas salivares que apresentam semelhança nos padrões histológicos, porém com comportamento clínico, tratamento e prognóstico completamente diferentes. A galectina-3 é uma proteína multifuncional da família das lectinas que está envolvida em vários fenômenos biológicos como crescimento celular, adesão celular, diferenciação celular e apoptose. Além disso, tem sido estudada como um marcador de invasão tumoral e metástase. O objetivo deste trabalho foi estudar qualitativamente a expressão imunoistoquímica da galectina-3 em 14 casos de carcinoma adenóide cístico (2 do subtipo tubular, 4 do subtipo sólido e 8 do subtipo cribriforme) e em 12 casos de adenocarcinoma polimorfo de baixo grau de malignidade com padrões histológicos variados, incluindo os padrões lobular, tubular e cribriforme. Espécimes de glândula salivar normal foram também incluídos na amostra. Nas glândulas salivares normais houve forte marcação da galectina-3 no núcleo e no citoplasma das células luminais dos ductos. Nos carcinomas adenóides císticos houve uma maior marcação da galectina-3 no subtipo tubular, localizada apenas nas células luminais das estruturas tubulares. Nos subtipos sólido e cribriforme a marcação foi menor, mas sempre localizada nas células que circundavam espaços luminais. Em todos os casos de carcinomas adenóides císticos estudados a marcação foi predominantemente nuclear. Nos adenocarcinomas polimorfos de baixo grau de malignidade a marcação da galectina-3 foi predominantemente citoplasmática em praticamente todas as células neoplásicas. Diante disso podemos sugerir que, nas neoplasias estudadas, a expressão da galectina-3 parece estar mais relacionada à diferenciação celular do que à progressão tumoral e ao prognóstico.<br>Adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma are malignant neoplasms of salivary glands which are similar in histologic patterns but very different in clinical behavior, treatment and prognosis. Galectin-3 is a multifunctional protein of a growing family of beta-galactoside-binding animal lectins which is implicated in a variety of biological events such as tumor cell adhesion, proliferation, differentiation and angiogenesis. This protein was found to be implicated in cellular transformation, and a correlation between its expression and cancer progression and metastasis has been described. The aim of this study was to determine the galectin-3 immunoprofile in 14 cases of adenoid cystic carcinoma (2 cases of tubular subtype, 4 cases of solid subtype and 8 cases of cribriform subtype) and in 12 cases of polymorphous low-grade adenocarcinoma with different histologic patterns, included lobular, tubular and cribriform. Moreover, slides of normal salivary glands were included. In normal salivary glands there were strong nuclei and cytoplasmic staining for galectin-3 in ductal luminal cells. Adenoid cystic carcinomas showed specific staining in luminal cells mainly in the nuclei. In the tubular subtype of adenoid cystic carcinoma galectin-3 was strong in the luminal cells of the ductiform structures. The cribriform and solid subtypes showed a few positive cells for galectin-3 only in the luminal cells of small ducts presenting in the cribriform structures and in solid nests respectly. In the cases of polymorphous low-grade adenocarcinoma, independent of the histologic architecture, all tumor cells revealed a positive cytoplasmic reaction with the galectin-3 antibody. Galectin-3 expression seems to be related to cell differentiation more than tumor progression and prognosis in the neoplasms studied.
APA, Harvard, Vancouver, ISO, and other styles
2

Rejas, Roberto Anaximandro Garcia. "Estudo da imunoexpressão das proteínas C-JUN e JUNB em carcinoma adenóide cístico e adenocarcinoma polimorfo de baixo grau de malignidade de glândulas salivares." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/23/23141/tde-20012009-151227/.

Full text
Abstract:
O carcinoma adenóide cístico e o adenocarcinoma polimorfo de baixo grau de malignidade são neoplasmas de glândulas salivares. O carcinoma adenóide cístico pode apresentar-se em glândulas salivares maiores e menores, porém o adenocarcinoma polimorfo de baixo grau de malignidade acomete principalmente as glândulas salivares menores distribuidas na cavidade oral. Ambos os tumores compartilham muitas características comuns, como a alta propensão de invasão perineural e o padrão de infiltracão: sólido, tubular e cribriforme. Mas o carcinoma adenoide cístico e o adenocarcinoma polimorfo de baixo grau são tipos distintos de adenocarcinomas com prognóstico diferente, que ocasionalmente podem resultar em um diágnóstico errado. As proteínas c-jun e junB são membros da familia JUN, capazes de homodimerizar ou heterodimerizar com c-fos ou com outras proteinas bzip. Evidências das funcões específicas das subunidades do AP-1 foram mostradas por cjun e junB, que atúam antagónicamente no controle da transformação celular, diferenciação e expressão do AP-1 dependente do gene alvo. Mas a função de ambos é complexa e pode depender do tipo celular. O objetivo deste estudo foi determinar a expressão imunoistoquímica das proteínas c-jun e junB em 13 casos de carcinoma adenoide cístico e 12 de adenocarcinoma polimorfo de baixo grau de malignidade de glándulas salivares. Espécimes de mucosa normal foram incluídos e evidenciaram forte marcação nuclear e citoplasmática para junB e c-jun respectivamente. No presente estudo, independente da arquitetura histológica, ambos tumores mostraram muitas células tumorais com marcação nuclear e citoplasmática para a proteína c-jun e ausente para a proteína junB. As lesões do adenocarcinoma polimorfo de baixo grau de malignidade expressaram um maior número de células com marcação nuclear quando comparados ao do carcinoma adenoide císticode de mais baixo grau. De acordo com este estudo e com alguns estudos publicados na literatura, a c-jun é expressa em tumores de baixo grau e parece estar mais relacionada à diferenciação celular do que à proliferação celular.<br>Adenoid cystic carcinoma and polymorphous low grade are salivary gland neoplasms. ACC can arise in both, major or minor salivary glands. However, Polymorphous lowgrade adenocarcinoma, occurs specifically in minor salivary glands dispersed in the oral cavity. They share many common histologic features, as infiltrating solid, tubular and cribiform patterns and also high propensity for perineural invasion. Nevertheless, adenoid cystic carcinoma and polymorphous low grade are distinct types of adenocarcinomas with different prognosis, which occasionally may result in a diagnostic pitfall. C-jun and junB are family JUN members that may form homodimerizes or heterodimerizes with c-fos or other bzip proteins. Evidence for specific functions of AP-1 subunits was shown for c-jun and junB, which act antagonistically to control cell transformation, differentiation and expression of AP-1 depending on the target genes. However, the role of both of them is complex and it depends on cell type. The aim of this study was to determine immunohistochemistry of c -jun and junB expression in 13 cases of adenoid cystic carcinoma and 12 cases of polymorphous carcinoma low-grade adenocarcinoma of salivary glands. Moreover slides of normal mucosa were included and there were strong nuclei and cytoplasmic for junB and c-jun respectly. In the present study, independent of the histologic architecture, in both tumors shown many tumoral cells presented nuclear and cytoplasmic staining of c-jun and were absent to the protein junB. In polymorphous low-grade adenocarcinoma lesions expressed in a greater number cells staining than in the adenoid cystic carcinoma of the most lowgrade. According with this study and with some studies of the literature, the c-jun is expressed in low-grade tumors and seems to be related to cell differentiation more than with cell proliferation.
APA, Harvard, Vancouver, ISO, and other styles
3

Ferrazzo, Kivia Linhares. "Estudo da expressão imunoistoquímica da proteína galectina-3 associada à -catenina e ciclina D1 em carcinoma adenóide cístico e adenocarcinoma polimorfo de baixo grau de malignidade de glândulas salivares." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/23/23141/tde-20012009-105028/.

Full text
Abstract:
Neoplasias malignas das glândulas salivares são lesões raras e o mecanismo pelo qual esses tumores progridem ainda não está completamente esclarecido na literatura. A galectina-3 é uma proteína multifuncional expressa em uma grande quantidade de tecidos normais, mas que também tem sido associada à progressão tumoral de neoplasias malignas da tireóide, próstata e neoplasias gástricas. Estudos prévios demonstraram que a galectina-3 está também expressa em algumas neoplasias malignas das glândulas salivares como carcinoma adenóide cístico e adenocarcinoma polimorfo de baixo grau de malignidade. Recentemente foi sugerido que a superexpressão da galectina-3 controla alterações nos níveis de expressão de alguns reguladores do ciclo celular, dentre eles a ciclina D1. Além disso, outros estudos revelaram que a ciclina D1 é ativada pela -catenina de uma maneira dependente da galectina-3. O objetivo desse trabalho foi comparar a marcação imunoistoquímica nuclear e / ou citoplasmática da galectina-3 no carcinoma adenóide cístico e adenocarcinoma polimorfo de baixo grau tentando relacioná-la à marcação da -catenina e ciclina D1. Foram realizadas reações de imunoistoquímica para as três proteínas em 15 casos de carcinoma adenóide cístico e em 15 casos de adenocarcinoma polimorfo de baixo grau utilizando-se material parafinado. Para a galectina-3 os carcinomas adenóides císticos apresentaram marcação imunoistoquímica apenas nas células luminais, predominantemente no núcleo. Todos os casos de adenocarcinoma polimorfo de baixo grau revelaram uma marcação predominantemente citoplasmática para essa proteína. Ambos os tumores exibiram intensa marcação citoplasmática e/ou nuclear para a -catenina na maioria dos casos. Não houve imunorreatividade para a ciclina D1 em 14/15 casos de adenocarcinoma polimorfo de baixo grau. Em contraste, os carcinomas adenóides císticos revelaram marcação nuclear específica para a ciclina D1 em 10 de 15 casos estudados em mais de 5% das células neoplásicas e essa marcação estava associada à marcação citoplasmática e nuclear da galectina-3 (p<0,05). Esses resultados sugerem que nos carcinomas adenóides císticos a expressão da galectina-3 pode exercer uma função de proliferação celular e parece estar relacionada à diferenciação celular no adenocarcinoma polimorfo de baixo grau. Além disso, a perda de expressão da galectina-3 no carcinoma adenóide cístico pode estar associada a um comportamento clínico mais agressivo dessa lesão. Embora a -catenina pareça exercer algum papel no mecanismo de carcinogênese dessas duas lesões, ela não parece se ligar à galectina-3 para ativar a ciclina D1.<br>Salivary gland tumors are uncommon and the mechanism by which malignant tumors progresses is still undefined. In a previous study it was shown that galectin-3 is expressed in malignant salivary gland neoplasms as adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Galectin-3 is a multifunctional protein of a group of galactoside-binding lectins expressed in a variety of normal cells, but also has been implicated in tumor progression of some malignancies as thyroid, prostate and gastric cancers. Recently, it has been suggested that galectin-3 may be an important mediator of the -catenin/Wnt pathway. Moreover, nuclear galectin-3 expression has been implicated in cell proliferation, promoting cyclin D1 activation. Thus, in the present study we aimed to correlate galectin-3 expression, either nuclear or cytoplasmic, with the expression of -catenin (nuclear/cytoplasmic) and cyclin D1 (nuclear) in 15 cases of adenoid cystic carcinoma and in 15 cases of polymorphous low-grade adenocarcinoma. For galectin-3, adenoid cystic carcinomas showed specific staining only in luminal cells, mainly in the nuclei. In the cases of polymorphous low-grade adenocarcinoma, all tumor cells revealed a positive, mostly cytoplasmic, reaction to galectin-3. Both tumors showed intense cytoplasmic/nuclear staining for -catenin in the majority of cases. Cyclin D1 immunoreactivity was not detected in 14 of the 15 polymorphous low-grade adenocarcinomas studied. In contrast, adenoid cystic carcinomas showed specific nuclear staining for cyclin D1 in 10 of 15 cases studied in more than 5% of the neoplastic cells. Cyclin D1 expression was correlated with cytoplasmic and nuclear galectin-3 expression in adenoid cystic carcinomas (p<0,05). These results suggest that in adenoid cystic carcinoma galectin-3 may play a role in cellular proliferation through cyclin D1 activation. In polymorphous low-grade adenocarcinoma gal-3 expression seems to be associated with cellular differentiation. In addition, loss of cytoplasmic expression of galectin-3 in adenoid cystic carcinomas may be related to a more aggressive behavior of these lesions. Although -catenin seems to play a role in carcinogenesis, in both lesions, it seems that it does not bind to galectin-3 for cyclin D1 stimulation.
APA, Harvard, Vancouver, ISO, and other styles
4

Lascane, Nelise Alexandre da Silva. "Expressão imuno-histoquímica das proteínas Jab1, p27, c-jun e c-fos no adenoma pleomórfico, adenocarcinoma polimorfo de baixo grau e carcinoma adenoide cístico das glândulas salivares." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/23/23141/tde-18032015-173058/.

Full text
Abstract:
Os tumores de glândula salivar compreendem em torno de 2 a 6,5% dos tumores de cabeça e pescoço. Entre os tumores de glândula salivar, o adenoma pleomórfico é benigno e o mais comum. O carcinoma adenoide cístico e adenocarcinoma polimorfo de baixo grau encontram-se entre os mais frequentes malignos. Jab1 é uma de muitas proteínas que afetam diversos estágios da tumorigênese sendo importante na regulação variadas vias de sinalização e/ou proteínas como p27 e AP-1, a última composta por c-jun e c-fos, que são principalmente relacionadas com o ciclo celular e proliferação celular. O objetivo desse trabalho foi avaliar a expressão imuno-histoquímica das proteínas Jab1, p27, c-jun e c-fos no adenoma pleomórfico, adenocarcinoma polimorfo de baixo grau e carcinoma adenoide cístico das glândulas salivares. Foi realizada análise imuno-histoquímica semi-quantitativa das células marcadas nos tumores de glândula salivar e glândula salivar normal de acordo com o escore 0 (células sem expressão), 1(> 0 <= 5% de células marcadas), 2 (> 5 <= 50%) and 3 (> 50%). Para Jab1, c-jun e c-fos foi considerado apenas marcação nuclear e para p27, nuclear e citoplasmática, separadamente. Os resultados foram analisados utilizando-se os testes de Kruskal-Wallis, de Mann-Whitney, do Qui-quadrado e o teste de correlação de Spearman, cujo nível de significância foi de p<0,05 e processados com o auxílio do software GraphPad Prisma 5.0. A análise estatística revelou que a expressão de Jab1 foi significante no adenoma pleomórfico e no carcinoma adenoide cístico em relação aos ductos e no adenocarcinoma polimorfo de baixo grau em relação ao carcinoma adenoide cístico (p=0,0136, 0,0001 e 0,0344, respectivamente); a expressão de p27 nuclear foi significante no adenoma pleomórfico e no adenocarcinoma polimorfo de baixo grau quando comparados ao carcinoma adenoide cístico (p=0,0074 e 0,0004, respectivamente) e a expressão citoplasmática em todos os grupos quando comparados aos ácinos; c-fos, a expressão foi significativa nos ductos ao compará-los ao adenoma pleomórfico, adenocarcinoma polimorfo de baixo grau e carcinoma adenoide cístico (p=0,0002, 0,0048 e 0,0352, respectivamente). O teste de correlação de Spearman de Jab1, p27, c-jun e c-fos em cada lesão separadamente revelou que no adenoma pleomórfico houve correlação significativa entre Jab1 e p27 (r=0,371; p=0,020) e entre c-jun e c-fos (r=0,452; p=0,004). No adenocarcinoma polimorfo de baixo grau, houve correlação entre Jab1 e p27 (r=0,494; p=0,044) e no carcinoma adenoide cístico, entre p27 e c-fos (r=0,513; p=0,035). Foi concluído que a tumorigênese do adenoma pleomórfico, adenocarcinoma polimorfo de baixo grau e carcinoma adenoide cístico parece estar associada à expressão de Jab1 e p27.<br>Salivary gland tumors comprise about 2 to 6.5% of the head and neck tumors. Among the salivary gland tumors, pleomorphic adenoma is the most common and benign tumor. Adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma are the most frequent malignant tumors. Jab1 is one of many proteins which affects many stages of the tumorigenesis and regulates positively and negatively several pathways and/or proteins such as p27 and AP-1, the latter composed by c-jun and c-fos, which are mostly related to cell cycle and cell proliferation. The aim of this study was to evaluate the immunoexpression of the proteins Jab1, p27, c-jun and c-fos in pleomorphic adenoma, polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma of the salivary glands. The semi-quantitative immunohistochemical analysis was performed in salivary gland tumors and in normal salivary gland according to the score 0 (no stained cells), 1 (> 0 <= 5% of stained cells), 2 (> 5 <= 50%) and 3 (> 50%). Nuclear immunostaining alone was considered for Jab1, c-jun and c-fos proteins and cytoplasmic and nuclear staining for p27. Results were analyzed in GraphPad Prisma 5.0 software using Kruskal-Wallis, Mann-Whitney and Chi-square tests and Spearman correlation test in which significancy level was p<0,05. Statistical analysis revealed that Jab1 expression was significant in pleomorphic adenoma and adenoid cystic carcinoma in relation to ducts and in polymorphous low-grade adenocarcinoma in relation to adenoid cystic carcinoma (p=0,0136, 0,0001 e 0,0344, respectively); the p27 nuclear expression was significant in pleomorphic adenoma and in polymorphous low-grade adenocarcinoma when compared to adenoid cystic carcinoma (p=0,0074 e 0,0004, respectively) and cytoplasmic immunostaining was significant in all groups when compared to acini; c-fos expression was significant in ducts if compared to pleomorphic adenoma, polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma (p=0,0002, 0,0048 e 0,0352, respectively). Spearman correlation test to Jab1, p27, c-jun and c-fos in each lesion separately revealed significant correlation between Jab1 and p27 (r=0,371; p=0,020) and c-jun and c-fos (r=0,452; p=0,004) in pleomorphic adenoma. There was correlation between Jab1 and p27 (r=0,494; p=0,044) in polymorphous low-grade adenocarcinoma and between p27 and c-fos (r=0,513; p=0,035) in adenoid cystic carcinoma. In conclusion, tumorigenesis in pleomorphic adenoma, polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma seems to be associated to expression of Jab1 and p27.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Polymorphous low-grade adenocarcinoma"

1

Hellquist, Henrik, and Alena Skalova. "Polymorphous Low-Grade Adenocarcinoma." In Histopathology of the Salivary Glands. Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-540-46915-5_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Klijanienko, Jerzy, and Philippe Vielh. "Polymorphous Low-Grade Adenocarcinoma, Cytological Findings." In Encyclopedia of Pathology. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-33286-4_962.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Prasad, Manju L., and Christel Haberland. "Polymorphous Low-Grade Adenocarcinoma, Salivary Glands of." In Encyclopedia of Geoarchaeology. Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-3-319-28618-1_1833.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Polymorphous Low-Grade Adenocarcinoma." In Diagnostic Pathology: Head and Neck. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-323-39255-6.50174-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Polymorphous Low-Grade Adenocarcinoma." In Diagnostic Pathology: Cytopathology. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-323-54763-5.50154-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Chapter 17 Malignant Minor Salivary Gland Tumors (Adenoidcystic, Mucoepidermoid, Adenocarcinoma, Low-Grade Polymorphous Adenocarcinoma)." In Atlas of Head and Neck Imaging: The Extracranial Head and Neck, edited by Suresh K. Mukherji and Vincent Chong. Georg Thieme Verlag, 2004. http://dx.doi.org/10.1055/b-0034-59126.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Chapter 80 Malignant Minor Salivary Gland Tumors Adenoidcystic, Mucoepidermoid, Adenocarcinoma, Low-Grade Polymorphous Adenocarcinoma." In Atlas of Head and Neck Imaging: The Extracranial Head and Neck, edited by Suresh K. Mukherji and Vincent Chong. Georg Thieme Verlag, 2004. http://dx.doi.org/10.1055/b-0034-59231.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Chapter 183 Malignant Minor Salivary Gland Tumors (Adenoidcystic, Mucoepidermoid, Adenocarcinoma, Low Grade Polymorphous Adenocarcinoma)." In Atlas of Head and Neck Imaging: The Extracranial Head and Neck, edited by Suresh K. Mukherji and Vincent Chong. Georg Thieme Verlag, 2004. http://dx.doi.org/10.1055/b-0034-59339.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"Chapter 195 Malignant Minor Salivary Gland Tumors (Adenoidcystic, Mucoepidermoid, Adenocarcinoma, Low Grade Polymorphous Adenocarcinoma)." In Atlas of Head and Neck Imaging: The Extracranial Head and Neck, edited by Suresh K. Mukherji and Vincent Chong. Georg Thieme Verlag, 2004. http://dx.doi.org/10.1055/b-0034-59352.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"Chapter 149 Malignant Minor Salivary Gland Tumors (Adenoid cystic, Mucoepidermoid, Adenocarcinoma, Low-Grade Polymorphous Adenocarcinoma)." In Atlas of Head and Neck Imaging: The Extracranial Head and Neck, edited by Suresh K. Mukherji and Vincent Chong. Georg Thieme Verlag, 2004. http://dx.doi.org/10.1055/b-0034-59303.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Polymorphous low-grade adenocarcinoma' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography